GlassBury AI combines agentic patient matching with culturally sensitive community education to eliminate healthcare disparities. By pairing AI with expert-curated workshops, we build the trust necessary to connect underrepresented patients with life-changing clinical trials.
Why New Alzheimer’s Treatments are Leaving Atypical Patients Behind
There is a massive blind spot in the current landscape of neurodegenerative care, and it’s one that should keep every health-tech developer awake at night. For decades, the public and medical consciousness has viewed Alzheimer’s disease through a single, narrow lens: the loss of memory. We imagine the grandmother who forgets a name or the father who loses his keys.
How Artificial Intelligence is Reshaping Drug Target Identification
In the labyrinthine world of pharmaceutical research, the quest for effective new drugs often resembles a painstaking expedition through an uncharted wilderness. The initial and perhaps most critical phase of this journey is the identification of viable drug targets—specific molecules within the body that play a pivotal role in a disease's progression and can be modulated by therapeutic interventions. Traditionally, this process has been slow, expensive, and fraught with uncertainty. However, a revolutionary force is now transforming this landscape: Artificial Intelligence (AI). By harnessing the power of vast datasets and sophisticated algorithms, AI is rapidly reshaping the field of drug target identification, offering unprecedented speed, precision, and potential.